Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 101.6% during the fourth quarter, Holdings Channel reports. The firm owned 966,049 shares of the biopharmaceutical company’s stock after purchasing an additional 486,827 shares during the period. Trexquant Investment LP’s holdings in Amicus Therapeutics were worth $9,100,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in FOLD. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth $55,000. R Squared Ltd acquired a new stake in Amicus Therapeutics during the fourth quarter worth about $79,000. Virtu Financial LLC purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth about $107,000. KBC Group NV lifted its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Finally, Sciencast Management LP purchased a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $100,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on FOLD. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $7.99 on Thursday. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -44.39, a PEG ratio of 1.51 and a beta of 0.69. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business’s 50 day moving average is $9.19 and its two-hundred day moving average is $9.90. Amicus Therapeutics, Inc. has a 52-week low of $7.85 and a 52-week high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.